WHO Pharmaceuticals Newsletter 2005, No. 01
(2005; 12 pages) View the PDF document
Table of Contents
Open this folder and view contentsREGULATORY MATTERS
Close this folderSAFETY OF MEDICINES
View the documentATAZANAVIRRITONAVIR - Not to be coadministered with omeprazole
View the documentCELECOXIB - Increased risk of cardiovascular events
View the documentDARBEPOETIN ALFA - Adverse outcomes associated with off-label dosing strategies
View the documentGALANTAMINE - Ineffective and possibly unsafe in mild cognitive impairment
View the documentGLUCOSAMINE - Concerns about hypercholesterolaemic effects
View the documentNAPROXEN - Long-term study indicates cardiovascular risk
View the documentNEVIRAPINE - Not recommended in women with CD4+ cell counts greater than 250 cells/mm3
View the documentPROPOFOL - Adverse events with both low- and high-rate infusions
View the documentROSUVASTATIN - More reports of rhabdomyolysis
Open this folder and view contentsDRUGS OF CURRENT INTEREST
Open this folder and view contentsFEATURE
 

GALANTAMINE - Ineffective and possibly unsafe in mild cognitive impairment

Canada. Janssen-Ortho Inc., under advice from Health Canada, is warning health professionals that according to preliminary data from two investigational studies, galantamine (Reminyl), a cholinesterase inhibitor, does not appear to be effective in treating patients with mild cognitive impairment (MCI). In addition, the initial analysis of both studies showed that 15 patients died in the galantamine (Reminyl) treatment group and five in the placebo treated group. The causes of death were mainly cardiovascular or cerebrovascular in nature.

Janssen-Ortho is reminding that galantamine (Reminyl) is approved only for the symptomatic treatment of patients with mild to moderate dementia of the Alzheimer's type and that it is not to be used outside of its approved indication.

Reference:

'Dear Health-care Professional' letter from Janssen-Ortho Inc., 21 January 2005. Available on the Internet at www.hc-sc.gc.ca

to previous section
to next section
 
 
The WHO Essential Medicines and Health Products Information Portal was designed and is maintained by Human Info NGO. Last updated: October 29, 2018